The predictive value of serum myeloperoxidase for vasospasm in patients with aneurysmal subarachnoid hemorrhage

Michael Lim, Regina S. Bower, Ying Wang, Leroy Sims, Mark R. Bower, Camara Quintana Joaquin, Gordon Li, Samuel Cheshier, Griffith R. Harsh, Gary K. Steinberg, Samira Guccione

Research output: Contribution to journalArticle

Abstract

Vasospasm is a major contributor to morbidity and mortality in aneurysmal subarachnoid hemorrhage (SAH), with inflammation playing a key role in its pathophysiology. Myeloperoxidase (MPO), an inflammatory marker, was examined as a potential marker of vasospasm in patients with SAH. Daily serum samples from patients with aneurysmal SAH were assayed for MPO, and transcranial Doppler (TCDs) and neurological exams were assessed to determine vasospasm. Suspected vasospasm was confirmed by angiography. Peak MPO levels were then compared with timing of onset of vasospasm, based on clinical exams, TCDs and cerebral angiography. Patients with vasospasm had a mean MPO level of 115.5 ng/ml, compared to 59.4 ng/ml in those without vasospasm, 42.0 ng/ml in those with unruptured aneurysms, and 4.3 ng/ml in normal controls. In patients who experienced vasospasm, MPO was elevated above the threshold on the day of, or at any point prior to, vasospasm in 10 of 15 events (66.7%), and on the day of, or within 2 days prior to, vasospasm in 8 of 15 events (53.3%). Elevated serum MPO correlates with clinically evident vasospasm following aneurysmal SAH. The potential utility of MPO as a marker of vasospasm is discussed.

Original languageEnglish (US)
Pages (from-to)413-419
Number of pages7
JournalNeurosurgical Review
Volume35
Issue number3
DOIs
StatePublished - Jul 2012

Fingerprint

Subarachnoid Hemorrhage
Peroxidase
Serum
Cerebral Angiography
Aneurysm
Angiography
Inflammation
Morbidity
Mortality

Keywords

  • Aneurysm
  • Myeloperoxidase
  • Subarachnoid hemorrhage
  • Vasospasm

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery

Cite this

The predictive value of serum myeloperoxidase for vasospasm in patients with aneurysmal subarachnoid hemorrhage. / Lim, Michael; Bower, Regina S.; Wang, Ying; Sims, Leroy; Bower, Mark R.; Joaquin, Camara Quintana; Li, Gordon; Cheshier, Samuel; Harsh, Griffith R.; Steinberg, Gary K.; Guccione, Samira.

In: Neurosurgical Review, Vol. 35, No. 3, 07.2012, p. 413-419.

Research output: Contribution to journalArticle

Lim, M, Bower, RS, Wang, Y, Sims, L, Bower, MR, Joaquin, CQ, Li, G, Cheshier, S, Harsh, GR, Steinberg, GK & Guccione, S 2012, 'The predictive value of serum myeloperoxidase for vasospasm in patients with aneurysmal subarachnoid hemorrhage', Neurosurgical Review, vol. 35, no. 3, pp. 413-419. https://doi.org/10.1007/s10143-012-0375-4
Lim, Michael ; Bower, Regina S. ; Wang, Ying ; Sims, Leroy ; Bower, Mark R. ; Joaquin, Camara Quintana ; Li, Gordon ; Cheshier, Samuel ; Harsh, Griffith R. ; Steinberg, Gary K. ; Guccione, Samira. / The predictive value of serum myeloperoxidase for vasospasm in patients with aneurysmal subarachnoid hemorrhage. In: Neurosurgical Review. 2012 ; Vol. 35, No. 3. pp. 413-419.
@article{6d7b36a806cf4f35942aaa8384469786,
title = "The predictive value of serum myeloperoxidase for vasospasm in patients with aneurysmal subarachnoid hemorrhage",
abstract = "Vasospasm is a major contributor to morbidity and mortality in aneurysmal subarachnoid hemorrhage (SAH), with inflammation playing a key role in its pathophysiology. Myeloperoxidase (MPO), an inflammatory marker, was examined as a potential marker of vasospasm in patients with SAH. Daily serum samples from patients with aneurysmal SAH were assayed for MPO, and transcranial Doppler (TCDs) and neurological exams were assessed to determine vasospasm. Suspected vasospasm was confirmed by angiography. Peak MPO levels were then compared with timing of onset of vasospasm, based on clinical exams, TCDs and cerebral angiography. Patients with vasospasm had a mean MPO level of 115.5 ng/ml, compared to 59.4 ng/ml in those without vasospasm, 42.0 ng/ml in those with unruptured aneurysms, and 4.3 ng/ml in normal controls. In patients who experienced vasospasm, MPO was elevated above the threshold on the day of, or at any point prior to, vasospasm in 10 of 15 events (66.7{\%}), and on the day of, or within 2 days prior to, vasospasm in 8 of 15 events (53.3{\%}). Elevated serum MPO correlates with clinically evident vasospasm following aneurysmal SAH. The potential utility of MPO as a marker of vasospasm is discussed.",
keywords = "Aneurysm, Myeloperoxidase, Subarachnoid hemorrhage, Vasospasm",
author = "Michael Lim and Bower, {Regina S.} and Ying Wang and Leroy Sims and Bower, {Mark R.} and Joaquin, {Camara Quintana} and Gordon Li and Samuel Cheshier and Harsh, {Griffith R.} and Steinberg, {Gary K.} and Samira Guccione",
year = "2012",
month = "7",
doi = "10.1007/s10143-012-0375-4",
language = "English (US)",
volume = "35",
pages = "413--419",
journal = "Neurosurgical Review",
issn = "0344-5607",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - The predictive value of serum myeloperoxidase for vasospasm in patients with aneurysmal subarachnoid hemorrhage

AU - Lim, Michael

AU - Bower, Regina S.

AU - Wang, Ying

AU - Sims, Leroy

AU - Bower, Mark R.

AU - Joaquin, Camara Quintana

AU - Li, Gordon

AU - Cheshier, Samuel

AU - Harsh, Griffith R.

AU - Steinberg, Gary K.

AU - Guccione, Samira

PY - 2012/7

Y1 - 2012/7

N2 - Vasospasm is a major contributor to morbidity and mortality in aneurysmal subarachnoid hemorrhage (SAH), with inflammation playing a key role in its pathophysiology. Myeloperoxidase (MPO), an inflammatory marker, was examined as a potential marker of vasospasm in patients with SAH. Daily serum samples from patients with aneurysmal SAH were assayed for MPO, and transcranial Doppler (TCDs) and neurological exams were assessed to determine vasospasm. Suspected vasospasm was confirmed by angiography. Peak MPO levels were then compared with timing of onset of vasospasm, based on clinical exams, TCDs and cerebral angiography. Patients with vasospasm had a mean MPO level of 115.5 ng/ml, compared to 59.4 ng/ml in those without vasospasm, 42.0 ng/ml in those with unruptured aneurysms, and 4.3 ng/ml in normal controls. In patients who experienced vasospasm, MPO was elevated above the threshold on the day of, or at any point prior to, vasospasm in 10 of 15 events (66.7%), and on the day of, or within 2 days prior to, vasospasm in 8 of 15 events (53.3%). Elevated serum MPO correlates with clinically evident vasospasm following aneurysmal SAH. The potential utility of MPO as a marker of vasospasm is discussed.

AB - Vasospasm is a major contributor to morbidity and mortality in aneurysmal subarachnoid hemorrhage (SAH), with inflammation playing a key role in its pathophysiology. Myeloperoxidase (MPO), an inflammatory marker, was examined as a potential marker of vasospasm in patients with SAH. Daily serum samples from patients with aneurysmal SAH were assayed for MPO, and transcranial Doppler (TCDs) and neurological exams were assessed to determine vasospasm. Suspected vasospasm was confirmed by angiography. Peak MPO levels were then compared with timing of onset of vasospasm, based on clinical exams, TCDs and cerebral angiography. Patients with vasospasm had a mean MPO level of 115.5 ng/ml, compared to 59.4 ng/ml in those without vasospasm, 42.0 ng/ml in those with unruptured aneurysms, and 4.3 ng/ml in normal controls. In patients who experienced vasospasm, MPO was elevated above the threshold on the day of, or at any point prior to, vasospasm in 10 of 15 events (66.7%), and on the day of, or within 2 days prior to, vasospasm in 8 of 15 events (53.3%). Elevated serum MPO correlates with clinically evident vasospasm following aneurysmal SAH. The potential utility of MPO as a marker of vasospasm is discussed.

KW - Aneurysm

KW - Myeloperoxidase

KW - Subarachnoid hemorrhage

KW - Vasospasm

UR - http://www.scopus.com/inward/record.url?scp=84862840875&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862840875&partnerID=8YFLogxK

U2 - 10.1007/s10143-012-0375-4

DO - 10.1007/s10143-012-0375-4

M3 - Article

C2 - 22370810

AN - SCOPUS:84862840875

VL - 35

SP - 413

EP - 419

JO - Neurosurgical Review

JF - Neurosurgical Review

SN - 0344-5607

IS - 3

ER -